Rheumatology 2000; 39: 1102-1109
© 2000 British Society for Rheumatology
Do patients with rheumatoid arthritis established on methotrexate and folic acid 5 mg daily need to continue folic acid supplements long term?
Department of Rheumatology, East Surrey Hospital,
1 Department of Rheumatology, Staffordshire Rheumatology Centre, Stoke-on-Trent and
2 Department of Mathematics, University of Keele, UK
Background. It is postulated that some aspects of methotrexate toxicity may be related to its action as an anti-folate. Folic acid (FA) is often given as an adjunct to methotrexate therapy, but there is no conclusive proof that it decreases the toxicity of methotrexate and there is a theoretical risk that it may decrease the efficacy of methotrexate.
Objectives. To look at the effect of stopping FA supplementation in UK rheumatoid arthritis (RA) patients established on methotrexate <20 mg weekly and FA 5 mg daily, to report all toxicity (including absolute changes in haematological and liver enzyme indices) and to report changes in the efficacy of methotrexate.
Methods. In a prospective, randomized, double-blind, placebo-controlled study, 75 patients who were established on methotrexate <20 mg weekly and FA 5 mg daily were asked to stop their FA and were randomized to one of two groups: placebo or FA 5 mg daily. Patients were evaluated for treatment toxicity and efficacy before entry and then at intervals of 3 months for 1 yr.
Results. Overall, 25 (33%) patients concluded the study early, eight (21%) in the group remaining on FA and 17 (46%) in the placebo group (P = 0.02). Two patients in the placebo group discontinued because of neutropenia. At 9 months there was an increased incidence of nausea in the placebo group (45 vs 7%, P = 0.001). The placebo group had significantly lower disease activity on a few of the variables measured, but these were probably not of clinical significance.
Conclusions. It is important to continue FA supplementation over the long term in patients on methotrexate and FA in order to prevent them discontinuing treatment because of mouth ulcers or nausea and vomiting. Our data suggest that FA supplementation is also helpful in preventing neutropenia, with very little loss of efficacy of methotrexate.
KEY WORDS: Methotrexate, Folic acid.
Correspondence to: S. M. Griffith, Department of Rheumatology, East Surrey Hospital, Canada Avenue, Redhill, Surrey RH1 5RH, UK.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Manna, E. Verrecchia, M. Diaco, M. Montalto, G. Cammarota, and G. Gasbarrini Folic acid supplementation during methotrexate treatment: nonsense? Rheumatology, April 1, 2005; 44(4): 563 - 564. [Full Text] [PDF]
|
|
|
|
|
|
A. J. Kinder, A. B. Hassell, J. Brand, A. Brownfield, M. Grove, and M. F. Shadforth The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions Rheumatology, January 1, 2005; 44(1): 61 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Whittle and R. A. Hughes Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review Rheumatology, March 1, 2004; 43(3): 267 - 271. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Palazzi, E. D'Amico, E. Pennese, and A. Petricca Normalization of methotrexate-induced high levels of serum transaminases after ursodeoxycholic acid administration in a rheumatoid arthritis patient Rheumatology, October 1, 2003; 42(10): 1266 - 1267. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sosin and S. Handa Lesson of the week: Low dose methotrexate and bone marrow suppression BMJ, February 1, 2003; 326(7383): 266 - 267. [Full Text] [PDF]
|
|
|
|
 |
|
 M CUTOLO, A SULLI, C PIZZORNI, B SERIOLO, and R H STRAUB Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis Ann Rheum Dis, August 1, 2001; 60(8): 729 - 735. [Full Text] [PDF]
|
|
|
|
|
|
N. Erb and G. D. Kitas Homocysteine modulation as a reason for continuous folic acid supplementation in methotrexate-treated rheumatoid arthritis patients Rheumatology, June 1, 2001; 40(6): 715 - 716. [Full Text] [PDF]
|
|